Ranking Profile - Hookipa Pharma Inc

Introduction

Hookipa Pharma Inc (Hookipa) is a clinical-stage biopharmaceutical company that develops novel class of immunotherapeutics against infectious diseases and cancers. Its pipeline products include HB-101, a prophylactic cytomegalovirus vaccine candidate; HB-202 and HB-201, immuno-oncology product candidates for the treatment of human papillomavirus-positive cancers; and HB-301, targeting prostate cancer. Hookipa’s proprietary arenavirus-based technologies, VaxWave, a replication-deficient viral vector, and TheraT, a replication-attenuated viral vector, are designed to induce antigen specific cytotoxic T cells and pathogen-neutralizing antibodies for prophylactic and therapeutic purposes activating body’s immune response. The company collaborates with Gilead Sciences Inc for the development of immunotherapies to treat HIV and Hepatitis B. It operates a research and preclinical development center in Vienna, Austria. Hookipa is headquartered in New York City, New York, the US.